Anxiety Disorders
Understanding fear, worry, and evidence-based treatments for anxiety conditions
Panic Disorder
Overview
Panic Disorder is characterized by unexpected and recurrent panic attacks—sudden episodes of intense fear or discomfort—accompanied by persistent concern about future attacks or maladaptive behavioral changes related to the attacks.
Panic Attack Symptoms
Panic attacks involve 4 or more of the following symptoms, peaking within minutes:
- Palpitations or accelerated heart rate
- Sweating
- Trembling or shaking
- Shortness of breath or smothering sensation
- Feelings of choking
- Chest pain or discomfort
- Nausea or abdominal distress
- Dizziness or feeling faint
- Chills or heat sensations
- Paresthesias (numbness/tingling)
- Feelings of unreality or detachment
- Fear of losing control or 'going crazy'
- Fear of dying
Evaluation & Diagnosis
Diagnosis is based on DSM-5-TR criteria requiring recurrent unexpected panic attacks followed by at least one month of persistent concern about additional attacks or significant behavioral changes related to the attacks.
Key Diagnostic Criteria
- Recurrent unexpected panic attacks
- ≥1 month of persistent concern about future attacks or their consequences
- Significant maladaptive behavioral changes (e.g., avoidance)
- Not due to substances or medical conditions
- Not better explained by other mental disorders
Screening Tools
Patient Health Questionnaire-Panic Module (PHQ-PD): 15-item questionnaire for panic disorder screening
GAD-7: Can also screen for panic disorder (cutoff ≥6 points, 85% sensitivity, 71% specificity)
Brief Panic Disorder Screen (BPDS): Short screening tool for clinical settings
Treatment Approaches
Both psychotherapy and medication are effective first-line treatments, often used individually or in combination based on patient preference and symptom severity.
First-Line Treatments
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Cognitive Behavioral Therapy (CBT)
Cognitive Behavioral Therapy
Components: Psychoeducation, cognitive restructuring, exposure therapy
Duration: 7-14 hours total, completed within 4 months
Techniques: In vivo exposure, interoceptive exposure, breathing retraining
First-Line Medications
- Citalopram (20-40 mg/day)
- Fluoxetine (20-60 mg/day)
- Fluvoxamine (50-300 mg/day)
- Sertraline (50-200 mg/day)
Start with low doses, gradual titration. Effects may take 2-8 weeks, full response ≥12 weeks.
Benzodiazepines
May be used for acute panic attacks in emergency settings or short-term augmentation, but not recommended for long-term treatment due to risk of dependence, tolerance, and adverse effects.
Background & Causes
The pathophysiology of panic disorder is multifactorial, involving genetic, environmental, and neurobiological factors affecting fear-processing systems in the brain.
Epidemiology
- Lifetime prevalence: 1.6%-5.2% in the U.S.
- More common in women (7%) than men (3.3%)
- 28% lifetime prevalence of panic attacks (broader than disorder)
- Patients typically experience 2-4 attacks per week
Risk Factors
- Female sex
- Young to middle age (20-54 years)
- Lower socioeconomic status
- Family history of mental health disorders
- Daily cigarette smoking
- Chronic stress and early life adversity
Neurobiological Mechanisms
Dysfunction in fear-processing circuits involving the amygdala, hippocampus, and prefrontal cortex. Abnormalities in neurotransmitter systems including norepinephrine, serotonin, GABA, and the HPA axis contribute to panic symptoms.
Prognosis & Outlook
Panic disorder typically follows a waxing and waning course. With appropriate treatment, many patients experience significant improvement, though relapse is common after treatment discontinuation.
Long-term Course: At 15-year follow-up, 51% still have panic symptoms and 18% still meet full diagnostic criteria.
Treatment Response: CBT has 19-30% relapse rates at ≥2-year follow-up; medication discontinuation leads to 50-89% relapse over 6 years.
Complications: Increased risk of agoraphobia, depression, substance use disorders, and cardiovascular complications.
Suicide Risk: 4-fold increased risk of suicidal ideation and behavior, especially with early onset, female sex, and comorbid mood disorders.
Functional Impact: Significant impairment in work, social functioning, and quality of life if untreated.
Treatment Duration
Patients who respond to medication should continue treatment for ≥1 year to reduce relapse risk. Gradual tapering over weeks to months is essential when discontinuing to prevent withdrawal symptoms.